Clinical trials
Participants With Advanced Solid Tumor Malignancies clinical trials
Below are recruiting participants with advanced solid tumor malignancies clinical trials, each written for real people, not researchers. We’re tracking 777 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07080242RecruitingPhase 1
Study of a new drug for small cell lung cancer and neuroendocrine tumors
This trial tests a new drug called BL-M14D1 for people with certain types of advanced lung cancer or neuroendocrine tumors that have stopped responding to other treatments. It may be an option if your cancer has a specific marker called DLL3.
Huntsville, AlabamaAges 18 years+ - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Anchorage, AlaskaAges 18 years+ - NCT06890338RecruitingPhase 2
Carboplatin and mirvetuximab for advanced ovarian cancer
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
Birmingham, AlabamaAges 18 years+ - NCT06333314RecruitingPhase 2
Dostarlimab for advanced dMMR/MSI cancers (not colorectal or endometrial)
This trial tests a drug called dostarlimab for people with certain advanced cancers that have a specific genetic feature (dMMR/MSI-H). The goal is to see if it helps shrink or control the cancer in people who haven't had other treatments yet.
AngersAges 18 years+ - NCT07593820RecruitingPhase 1
CAR-T Cell Study for Advanced HER2-Positive Cancers
This early-stage trial tests a new type of immune cell therapy called CAR-T cells, which are designed to recognize and attack cancer cells that have a protein called HER2. The cells are made from your own immune cells, trained in the laboratory, and given back to you. The study evaluates how safe the treatment is and whether it can shrink tumors.
Barcelona, CataloniaAges 18 years+ - NCT07469683RecruitingPhase 2
Combination therapy for advanced kidney cancer after first-line treatment
This trial tests a combination of two drugs (SLC-3010 and axitinib) versus axitinib alone for people with advanced clear cell kidney cancer that has progressed after initial treatment. It aims to see if the combination is safer and more effective.
SeoulAges 19 years+ - NCT07405164RecruitingPhase 3
Long-term extension study for people taking belzutifan
This study is for people who are already taking belzutifan in a related trial (LITESPARK-043) and want to continue treatment for advanced solid tumors or von Hippel-Lindau-related conditions. It tests the safety and effects of long-term use.
Boston, MassachusettsAges 18 years+ - NCT07061080RecruitingPhase 2
Tarlatamab for advanced digestive neuroendocrine cancer
This trial tests a new drug called Tarlatamab for people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) of the digestive system that has stopped responding to prior chemotherapy. The drug targets a protein called DLL3 found on some tumors, and researchers hope it can shrink or slow tumor growth.
Brest, BrestAges 18 years+ - NCT05598528Recruiting
Study why some lung cancers don’t respond to EGFR pills
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
Changsha, HunanAges 18 years+
Hear when a new Participants With Advanced Solid Tumor Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participants with advanced solid tumor malignancies?
- Yes. Clin2 currently lists 777 recruiting participants with advanced solid tumor malignancies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participants with advanced solid tumor malignancies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participants with advanced solid tumor malignancies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.